Finally, we will describe the different strategies used to target STAT3 or STAT5 and will discuss the potential future development of single or combined therapies to block STAT3 and/or STAT5A/5B activity/expression in hematologic cancers. The gene discussed is STAT3; the disease is hematopoietic and lymphoid cell neoplasm.